Natixis Advisors LLC Has $12.26 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Natixis Advisors LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 29.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 78,073 shares of the company’s stock after buying an additional 17,933 shares during the quarter. Natixis Advisors LLC owned 0.23% of TransMedics Group worth $12,258,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in TMDX. Oppenheimer & Co. Inc. raised its holdings in shares of TransMedics Group by 6.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 44,893 shares of the company’s stock worth $7,048,000 after buying an additional 2,748 shares in the last quarter. Victory Capital Management Inc. raised its stake in TransMedics Group by 11.3% during the third quarter. Victory Capital Management Inc. now owns 4,569 shares of the company’s stock worth $717,000 after acquiring an additional 464 shares in the last quarter. Aigen Investment Management LP bought a new position in shares of TransMedics Group in the third quarter worth about $523,000. Rakuten Securities Inc. acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $126,000. Finally, Entropy Technologies LP grew its holdings in shares of TransMedics Group by 34.7% during the 3rd quarter. Entropy Technologies LP now owns 10,471 shares of the company’s stock valued at $1,644,000 after purchasing an additional 2,700 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

TMDX stock opened at $77.20 on Thursday. The firm has a market cap of $2.59 billion, a PE ratio of 82.53 and a beta of 2.08. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a 50-day moving average price of $123.41 and a 200-day moving average price of $138.93. TransMedics Group, Inc. has a 1-year low of $66.76 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. The business’s revenue was up 63.7% compared to the same quarter last year. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

Analysts Set New Price Targets

TMDX has been the topic of several recent research reports. Robert W. Baird cut their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. TD Cowen reduced their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday. Oppenheimer dropped their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Piper Sandler reduced their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Stephens raised their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Buy” and a consensus price target of $131.80.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock worth $5,230,528 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.